Cardiovascular-kidney-metabolic syndrome: treatment gaps between women and men

Among patients with advanced cardiovascular-kidney-metabolic syndrome, women received several commonly indicated treatments less often than men. Yet the FINE-HEART analysis found a comparable adjusted risk of hospitalization for heart failure or cardiovascular death. These findings describe a disparity in care without establishing its cause.

Illustration of the heart and kidneys, organs involved in cardiovascular-kidney-metabolic syndrome.
NutritionEditorial illustration, not study data.

Three pooled trials, nearly 19,000 participants

This prespecified analysis brings together individual participant data from 18,991 people, including 6,664 women, who made up 35% of the sample. Two trials, FIDELIO-DKD and FIGARO-DKD, involved people with chronic kidney disease and type 2 diabetes. The third, FINEARTS-HF, focused on heart failure with mildly reduced or preserved ejection fraction.

The researchers compared several cardiovascular and kidney events, as well as mortality, by sex over a median follow-up of 2.9 years. They also investigated whether the effect of finerenone differed between women and men. The source material provides only the PubMed abstract, not the full text.

Fewer treatments despite advanced disease

Women were slightly older and more often had stage 4 cardiovascular-kidney-metabolic syndrome. At baseline, they were less likely to receive statins, renin–angiotensin system inhibitors, SGLT2 inhibitors or GLP-1 receptor agonists, among other treatments.

This gap alone does not demonstrate that every instance of non-prescribing was unjustified. The abstract does not allow individual indications, contraindications or reasons for the observed differences to be checked.

Different crude rates, but comparable adjusted risk

The rate of hospitalization for heart failure or cardiovascular death was 4.8 events per 100 person-years in women, compared with 3.9 in men. After statistical adjustment, the difference was no longer clear: the hazard ratio was 0.97, with a confidence interval of 0.89 to 1.06. Crude rates alone therefore do not establish a higher risk in women.

All-cause mortality, however, was lower in women after adjustment. For finerenone, the analyses detected no sex difference in its effect on cardiovascular events, kidney events or mortality. This absence of a detected difference does not prove that the effects are strictly identical.

Limitations to keep in mind

The comparison between women and men is not randomized, even though the data come from randomized trials. Unaccounted-for differences may remain after adjustment. These findings concern patients with advanced disease, not the general population. The full text, funding and conflicts of interest have not been checked.

What we can take away

Above all, this analysis calls for a closer look at gaps in care between women and men. It provides no evidence to support using finerenone differently based on sex alone.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.